FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of SR Pharma

SR Pharma plc announces IND for a 2nd siRNA therapeutic based on its unique proprietary chemistry

20-Mar-2007 - SR Pharma plc announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application (IND) for a second siRNA therapeutic which is based on the company 's unique proprietary chemistry. The product is AKIi-5, which is being developed by Quark Biotech Inc ...

acute kidney injury cardiovascular surgery chemistry +3

SR Pharma plc Announces Start of Phase I trial with Novel RNAi Therapeutic RTP-801i in Age- related Macular Degeneration (AMD)

07-Feb-2007 - SR Pharma plc announced that Quark Biotech Inc. has started a Phase I clinical trial with RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma plc. RTP-801i is based on Atugen's proprietary siRNA (AtuRNAi) technology and modifies the ...

clinical trials diseases Expression +2

SR Pharma Granted Core RNAi Patent by the European Patent Office

08-Jan-2007 - SR Pharma plc announced that the European Patent Office has granted the Company its core RNAi patent EP 03784183.0. This patent covers its novel, stabilised, small interfering RNA (siRNA) molecules with blunt ends and positional modifications. These proprietary siRNA molecules are referred to as ...

clinical trials nucleotides Pfizer +1

SR Pharma plc Announces Therapeutic Efficacy of Atu027 RNAi in pre-clinical Models of Pancreatic Cancer

01-Dec-2006 - SR Pharma plc announced that studies at the Charité Hospital have demonstrated the superior therapeutic efficacy of Atu027 RNAi in pre-clinical models of pancreatic cancer when compared to the standard care treatment. The data showed both inhibition of cancer growth and prevention of metastatic ...

clinical trials metastases pancreatic cancer

SR Pharma plc Announces Encouraging Results for Atu027 RNAi Showing Therapeutic Efficacy in Mouse Models of Pancreatic Cancer

15-Sep-2006 - SR Pharma plc and its operating subsidiary Atugen AG announce that studies at the Charité Hospital, Berlin have demonstrated the therapeutic efficacy of Atu027 RNAi in animal models of pancreatic cancer. The data showed both inhibition of cancer growth and prevention of metastatic spread, ...

clinical trials pancreatic cancer protein kinases +1

SR Pharma achieves key technical breakthrough with its lyophilized liposomal-based siRNA formulation

12-Jun-2006 - SR Pharma plc has announced that it has made a technical breakthrough in the formulation of siRNA drugs, that enables its proprietary lyophilized (freeze dried) liposomally formulated siRNA (AtuRNAi) drugs to be stored at room temperature and reconstituted in one simple step, thus providing ...

nanoparticles shelf life temperature +1